廣告
香港股市 將在 6 小時 55 分鐘 開市

  • 恒指

    18,868.71
    -326.89 (-1.70%)
     

  • 國指

    6,701.78
    -115.90 (-1.70%)
     

  • 上證綜指

    3,116.39
    -42.15 (-1.33%)
     

  • 道指

    39,069.26
    -601.78 (-1.52%)
     

  • 標普 500

    5,264.98
    -42.03 (-0.79%)
     

  • 納指

    16,718.66
    -82.88 (-0.49%)
     

  • Vix指數

    13.12
    +0.83 (+6.74%)
     

  • 富時100

    8,339.23
    -31.10 (-0.37%)
     

  • 紐約期油

    76.50
    -1.07 (-1.38%)
     

  • 金價

    2,335.70
    -57.20 (-2.39%)
     

  • 美元

    7.8086
    +0.0015 (+0.02%)
     

  • 人民幣

    0.9269
    0.0000 (0.00%)
     

  • 日圓

    0.0495
    -0.0000 (-0.04%)
     

  • 歐元

    8.4384
    -0.0100 (-0.12%)
     

  • Bitcoin

    67,047.78
    -2,450.48 (-3.53%)
     

  • CMC Crypto 200

    1,451.55
    -51.11 (-3.40%)
     

Here's What Key Metrics Tell Us About Insulet (PODD) Q1 Earnings

Zacks Equity Research
·2 分鐘文章

Insulet (PODD) reported $441.7 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 23.4%. EPS of $0.73 for the same period compares to $0.23 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $423.52 million, representing a surprise of +4.29%. The company delivered an EPS surprise of +87.18%, with the consensus EPS estimate being $0.39.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

廣告

Here is how Insulet performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- International Omnipod: $115.30 million compared to the $106.32 million average estimate based on six analysts. The reported number represents a change of +16.9% year over year.

  • Revenue- U.S. Omnipod: $317.70 million versus $311.93 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +22.7% change.

  • Revenue- Total Omnipod: $433 million compared to the $418.25 million average estimate based on six analysts. The reported number represents a change of +21.1% year over year.

  • Revenue- Drug Delivery: $8.70 million versus $5.56 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +1640% change.

View all Key Company Metrics for Insulet here>>>

Shares of Insulet have returned -1% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Insulet Corporation (PODD) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research